retatrutide phase 2 nejm 2023 weight loss percent 48 weeks Trial of for Obesity Retatrutide dose: the complete guide

Nevertheless, GLP-1 drugs are skyrocketing in popularity even in those without T2D

The same pattern is expected with retatrutide, though long-term discontinuation data is not yet available

This occurs because growth hormones can influence metabolic rate and blood sugar regulation

The transition process requires careful planning because you cannot simply swap one peptide for another mid-protocol

J Clin Endocrinol Metab (2016) 101(5):193544.10.1210/jc.2015-2583 167 JansenPLvan WervenJAartsEBerendsFJanssenIStokerJet alAlterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery

Earlier evidence for retatrutide comes from a Phase 2 trial in NEJM in 2023, which reported 24.2% weight loss at 12 mg over 48 weeks